Source: Virtual Congress 2020 – Recent innovations regarding the mechanisms and treatments of asthma
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Sullivan (Cork, Ireland), C. Ward (Newcastle upon Tyne, United Kingdom), D. Casey (Cork, Ireland), D. Flynn (Cork, Ireland), E. Hunt (Cork, Ireland), J. Eustace (Cork, Ireland), P. O' Byrne (Hamilton, Ontario, Canada), B. Plant (Cork, Ireland), J. Macsharry (Cork, Ireland), D. Murphy (Cork, Ireland). The impact of anti-IgE treatment on the airway microbiome in asthma.. 5284

Member's Comments

No comment yet.

Related content which might interest you: Anti-IL-5 therapy and the airway microbiome in asthma. Source: Virtual Congress 2020 – Recent innovations regarding the mechanisms and treatments of asthma Year: 2020 Effect of treatment with anti-IgE antibody on airway inflammation in mild asthma Source: Eur Respir J 2003; 22: Suppl. 45, 203s Year: 2003 Anti-IgE treatment, airway inflammation and remodelling in severe allergic asthma: current knowledge and future perspectives Source: Eur Respir Rev 2015; 24: 594-601 Year: 2015 A study to define the microbiome of the asthmatic airway. Source: International Congress 2017 – Clinical points to ponder in asthma Year: 2017 Same role and same treatment for airway eosinophilia in asthma and COPD? Source: Eur Respir J 2007; 29: 831-833 Year: 2007 The influence of obesity on bronchial hyperresponsiveness, airway and systemic inflammation, lung function and quality of life in patients with asthma Source: Annual Congress 2008 - Asthma: growing understanding of influential factors Year: 2008 The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma Source: Eur Respir J 2002; 20: 1088-1094 Year: 2002 The burden of airway hyperresponsiveness on the control of asthma Source: Annual Congress 2011 - Update on monitoring airway diseases Year: 2011 The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics Source: Eur Respir J 2001; 18: 254-261 Year: 2001 Comparative airway response to high- versus low-molecular weight agents in occupational asthma Source: Eur Respir J 2009; 33: 734-739 Year: 2009 The rationale for treating allergic asthma with anti-IgE Source: Eur Respir Rev 2007; 16: 61-66 Year: 2007 Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma Source: Eur Respir J 2002; 20: 73-78 Year: 2002 Improvements in asthma control and quality of life with omalizumab in allergic (IgE-mediated) asthma patients Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma Year: 2012 The airway microbiota and exacerbations of COPD Source: ERJ Open Res, 6 (3) 00168-2020; 10.1183/23120541.00168-2020 Year: 2020 Omalizumab reduces bronchial mucosal IgE and improves lung function in non-atopic asthma Source: Eur Respir J 2016; 48: 1593-1601 Year: 2016 Neuroregulatorial therapy of bronchial asthma Source: Eur Respir J 2002; 20: Suppl. 38, 55s Year: 2002 Omalizumab therapy reduces asthma exacerbations in children with severe allergic (IgE-mediated) asthma irrespective of lung function at baseline Source: Annual Congress 2009 - Difficult asthma in children: diagnostic and therapeutic challenges Year: 2009 Effect of humanized monoclonal anti-IgE antibody, omalizumab, on allergen challenge-induced nasal response in subjects with allergic rhinitis and allergic asthma Source: Eur Respir J 2001; 18: Suppl. 33, 36s Year: 2001 The nose–lung interaction in allergic rhinitis and asthma: united airways disease Source: Annual Congress 2007 - PG1 - Asthma: from bench to bedside Year: 2007